Glaucoma Therapeutics Market Size in the 7MM was ~USD 4,073 Million in 2022, is estimated to increase by 2034 at a significant CAGR | DelveInsight

DelveInsight's "Glaucoma Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Glaucoma Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Glaucoma Market Forecast. Click here to stay ahead in healthcare innovation @ Glaucoma Market Size [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Glaucoma Market Report

* Glaucoma remains undetected in most of the patients due to many factors. According to DelveInsight estimations, of 16,632,421 Glaucoma prevalent cases in 2022 in the 7MM, only 7,045,443 cases are estimated to have received a formal diagnosis.
* The US showed the highest Glaucoma diagnosed prevalent population compared to other 7MM countries, with nearly 2,451,089 cases in 2022. As per DelveInsight's estimates, the country alone accounts for nearly 35% of total diagnosed prevalent cases, for Glaucoma in the 7MM, followed by Japan, contributing 23% of all the Glaucoma cases.
* Glaucoma can affect both men and women, however the ratio of male to female Glaucoma patients suggest that female are predominantly affected more than males. In 2022, there were 3,234,796 cases of glaucoma among male population and 3,810,646 cases among female population.
* The Glaucoma diagnosed prevalent cases were further divided into open-angle glaucoma (OAG) and closed-angle glaucoma. The distribution showed that nearly 90% of glaucoma cases are of OAG type.
* Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma (SOAG) are two types of Open-angle glaucoma.
* Normal tension glaucoma (NTG) is a subtype of POAG occurring in the presence of normal IOP. As per DelveInsight's estimates, of all POAG cases in the 7MM, 52% were of NTG type.
* Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 701,946 cases, followed by France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population of glaucoma among EU4 and the UK in 2022.
* Japan accounted for 23% of the total diagnosed prevalent cases of Glaucoma in the 7MM in 2022.
* The leading Glaucoma Companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
* Promising Glaucoma Pipeline Therapies such as NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539 , and others.

Navigate the complexities of the Glaucoma Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Glaucoma Market Forecast. Click here to get more insights @ Glaucoma Treatment Market [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glaucoma Epidemiology Segmentation in the 7MM

* Total Glaucoma Prevalent Cases
* Total Glaucoma Diagnosed Prevalent Cases
* Glaucoma Type-specific Diagnosed Prevalent Cases
* Glaucoma Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma,
* Glaucoma Gender-specific Diagnosed Prevalent Cases
* Glaucoma Age-specific Diagnosed Prevalent Cases

Delve deep into the Glaucoma Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Glaucoma Market Forecast. Click here to shape the future @ Glaucoma Prevalence [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glaucoma Marketed Drugs

* ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%): Aerie Pharmaceuticals

Roclanda (in Europe), known as Rocklatan in the United States, is fixed-dose combination of a Rho kinase inhibitor and a prostaglandin F2a analog that reduces elevated intraocular pressure (IOP) in individuals diagnosed with open-angle glaucoma or hypertension. While it obtained approval in the US in March 2019, it gained approval in the European region in January 2021.

* DURYSTA (bimatoprost SR): AbbVie Inc.

DURYSTA is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable bimatoprost implant which is believed to lower IOP in humans by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). It imitates the effects of prostamides, specifically prostaglandin F2a.

Glaucoma Emerging Drugs

* NCX-470: Nicox Ophthalmics

NCX 470 is an investigational ophthalmic treatment by Nicox Ophthalmics designed to address ocular hypertension and open-angle glaucoma. It belongs to the second-generation nitric oxide (NO) category-donating prostaglandin analogs. This therapeutic candidate is administered through the ophthalmic route, targeting the prostaglandin F2 alpha receptor and soluble guanylate cyclase to achieve its effects.Based on a dual mechanism of action, NCX 470, a monotherapy, has the potential to be a new standard of care in reducing IOP glaucoma patients.

* TRS01: Tarsier Pharma

TRS01, a lead product of Tarsier Pharma in Phase III, is a breakthrough immunomodulatory approach based on a bio-inspired new molecular platform. TRS was developed to engineer the immune system. The platform approaches inflammatory diseases from within the system. The technology can effectively treat various autoimmune and inflammatory ocular diseases. Currently, TRS01 is being evaluated in a Phase III trial, called TRS4VISION, in patients with active noninfectious anterior uveitis and uveitic glaucoma. Uveitis glaucoma is a severe late-stage blinding condition that occurs when a patient develops glaucoma on top of uveitis

Unlock insights into the Glaucoma Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Glaucoma Market Forecast. Click here @ Glaucoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glaucoma Market Outlook

The primary objective of disease management is to reduce intraocular pressure (IOP), typically accomplished through the use of various drug classes such as prostaglandin analogs, beta-blockers, alpha-agonists, rho kinase inhibitors (ROCK), and carbonic anhydrase inhibitors. However, not all patients benefit from these treatments, as some may still experience optic nerve deterioration despite having normal IOP levels. In addition to pharmacological interventions, alternative measures such as incisional surgery, laser surgery, and medication are also commonly recommended.

Major Glaucoma Companies

Several Glaucoma Companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries , and others.

Glaucoma Drug Class Insights

Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of Glaucoma drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, rho kinase inhibitors (ROCK) and carbonic anhydrase inhibitors. Prostaglandin analogs increase fluid outflow, beta-blockers reduce fluid production, alpha-adrenergic agonists decrease fluid production and increase outflow, carbonic anhydrase inhibitors reduce fluid production, rho kinase inhibitors increase fluid outflow, and cholinergic agonists increase fluid drainage. The choice of medication depends on factors such as glaucoma severity, patient response, and potential side effects.

Gain a strategic edge in the Glaucoma Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Glaucoma Market Forecast. Click here to lead in advancements @ Glaucoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Glaucoma Market Research Report

* Coverage- 7MM
* Study Period- 2020-2034
* Glaucoma Companies- Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
* Glaucoma Therapies- NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.
* Glaucoma Market Dynamics: Glaucoma Market Drivers and Barriers
* Glaucoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Report Introduction

3. Country-wise Glaucoma Market Overview at a Glance

4. Glaucoma Market Overview by Class

5. Methodology of Glaucoma Epidemiology and Market

6. Executive Summary of Glaucoma

7. Key Events

8. Disease Background and Overview of Glaucoma

9. Epidemiology and Patient Population

10. Patient Journey

11. Glaucoma Marketed Therapies

12. Glaucoma Emerging Therapies

13. Glaucoma Market Analysis

14. Key Opinion Leaders' Views

15. Glaucoma SWOT Analysis

16. Glaucoma Unmet needs

17. Glaucoma Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glaucoma-therapeutics-market-size-in-the-7mm-was-usd-4073-million-in-2022-is-estimated-to-increase-by-2034-at-a-significant-cagr-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.